Login to Your Account



Pharma: Clinic Roundup


Monday, June 11, 2012
• UCB SA, of Brussels, Belgium, reported data from a post-hoc analysis of the Phase IIIb REALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) study, showing that, overall, 81.1 percent of rheumatoid arthritis patients treated with Cimzia (certolizumab pegol) during both the 12-week and open-label extension had a change in DAS28 equal to or greater than 1.2 and 89.3 percent had at least a 29 percent change in swollen joint count from baseline by week 12.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription